IFO
SPRO icon

Intrepid Family Office’s Spero Therapeutics SPRO Stock Holding History

Intrepid Family Office’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.1K Sell
16,279
-148,721
-90% -$353K 0.03% 38
2025
Q4 		$384K Buy
165,000
+55,000
+50% +$128K 0.33% 32
2025
Q3 		$207K Buy
+110,000
New +$242K 0.17% 33

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Intrepid Family Office's SPRO Position: Q1 2026 in Review

Intrepid Family Office reduced its Spero Therapeutics (SPRO) stake by 90% in Q1 2026, selling an estimated $353K and leaving 16,279 shares worth $38.1K. The position accounts for 0.03% of the portfolio, ranked #38.

Intrepid Family Office first reported a position in SPRO in Q3 2025 and has held it in 3 quarters since. The position peaked at $384K in Q4 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Intrepid Family Office held 16,279 shares of Spero Therapeutics worth $38.1K as of Q1 2026.
  • Intrepid Family Office sold 148,721 Spero Therapeutics shares in Q1 2026, an estimated $353K.
  • Spero Therapeutics made up 0.03% of Intrepid Family Office's portfolio in Q1 2026, its #38 holding.
  • Intrepid Family Office first reported a position in Spero Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Intrepid Family Office's Spero Therapeutics position peaked at $384K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Intrepid Family Office's 13F filing for Q1 2026, filed 15 May 2026.